Analysts: Sarepta’s Competitor Eliminated and 3 Other Research Notes to Browse

Sarepta (NASDAQ:SRPT): RW Baird says that the elimination of Prosensa (NASDAQ:RNA) as a potential competitor more than offsets any increase in risk for Sarepta following the failed Phase 3 trial for drisapersen. Baird said it has increased bullishness on Sarepta following today’s news and keeps an Outperform rating on the stock.